OBJECTIVES: To test the hypotheses that 1) patients with relapsing-remitting multiple sclerosis (RR-MS) exhibit a quantifiable decline in their whole-brain concentration of the neural marker N-acetyl-L-aspartate (WBNAA), that is 2) more sensitive than clinical changes and 3) may provide a practical outcome measure for proof-of-concept and larger phase III clinical trials. METHODS: Nineteen patients (5 men and 14 women) with clinically definite RR-MS, who were 33 ± 5 years old (mean ± SD), had a disease duration of 47 ± 28 months, and had a median Expanded Disability Status Scale (EDSS) score of 1.0 (range 0-5.5), underwent MRI and proton magnetic resonance spectroscopy ((1)H-MRS) semiannually for 2 years (5 time points). Eight matched control subjects underwent the protocol annually (3 time points). Their global N-acetyl-L-aspartate (1)H-MRS signal was converted into absolute amounts by phantom replacement and into WBNAA by dividing with the brain parenchymal volume, V(B), from MRI segmentation. RESULTS: The baseline WBNAA of the patients (10.5 ± 1.7 mM) was significantly lower than that of the controls (12.3 ± 1.3 mM; p < 0.002) and declined significantly (5%/year, p < 0.002) vs that for the controls who did not show a decline (0.4%/year, p > 0.7). Likewise, V(B) values of the patients also declined significantly (0.5%/year, p < 0.0001), whereas those of the controls did not (0.2%/year, p = 0.08). The mean EDSS score of the patients increased insignificantly from 1.0 to 1.5 (range 0-6.0) and did not correlate with V(B) or WBNAA. CONCLUSIONS: WBNAA of patients with RR-MS declined significantly at both the group and individual levels over a 2-year time period common in clinical trials. Because of the small sample sizes required to establish power, WBNAA can be incorporated into future studies.
OBJECTIVES: To test the hypotheses that 1) patients with relapsing-remitting multiple sclerosis (RR-MS) exhibit a quantifiable decline in their whole-brain concentration of the neural marker N-acetyl-L-aspartate (WBNAA), that is 2) more sensitive than clinical changes and 3) may provide a practical outcome measure for proof-of-concept and larger phase III clinical trials. METHODS: Nineteen patients (5 men and 14 women) with clinically definite RR-MS, who were 33 ± 5 years old (mean ± SD), had a disease duration of 47 ± 28 months, and had a median Expanded Disability Status Scale (EDSS) score of 1.0 (range 0-5.5), underwent MRI and proton magnetic resonance spectroscopy ((1)H-MRS) semiannually for 2 years (5 time points). Eight matched control subjects underwent the protocol annually (3 time points). Their global N-acetyl-L-aspartate (1)H-MRS signal was converted into absolute amounts by phantom replacement and into WBNAA by dividing with the brain parenchymal volume, V(B), from MRI segmentation. RESULTS: The baseline WBNAA of the patients (10.5 ± 1.7 mM) was significantly lower than that of the controls (12.3 ± 1.3 mM; p < 0.002) and declined significantly (5%/year, p < 0.002) vs that for the controls who did not show a decline (0.4%/year, p > 0.7). Likewise, V(B) values of the patients also declined significantly (0.5%/year, p < 0.0001), whereas those of the controls did not (0.2%/year, p = 0.08). The mean EDSS score of the patients increased insignificantly from 1.0 to 1.5 (range 0-6.0) and did not correlate with V(B) or WBNAA. CONCLUSIONS: WBNAA of patients with RR-MS declined significantly at both the group and individual levels over a 2-year time period common in clinical trials. Because of the small sample sizes required to establish power, WBNAA can be incorporated into future studies.
Authors: John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri Journal: Prog Neurobiol Date: 2007-01-05 Impact factor: 11.685
Authors: D K B Li; U Held; J Petkau; M Daumer; F Barkhof; F Fazekas; J A Frank; L Kappos; D H Miller; J H Simon; J S Wolinsky; M Filippi Journal: Neurology Date: 2006-05-09 Impact factor: 9.910
Authors: M Tiberio; D T Chard; D R Altmann; G Davies; C M Griffin; M A McLean; W Rashid; J Sastre-Garriga; A J Thompson; D H Miller Journal: J Neurol Date: 2005-11-24 Impact factor: 4.849
Authors: Eva Widerström-Noga; Varan Govind; James P Adcock; Bonnie E Levin; Andrew A Maudsley Journal: J Neurotrauma Date: 2016-01-15 Impact factor: 5.269
Authors: Matthew S Davitz; William E Wu; Brian J Soher; James S Babb; Ivan I Kirov; Jeffrey Huang; Girish Fatterpekar; Oded Gonen Journal: Magn Reson Imaging Date: 2016-08-28 Impact factor: 2.546
Authors: Valentina Di Pietro; Angela Maria Amorini; Barbara Tavazzi; Roberto Vagnozzi; Ann Logan; Giacomo Lazzarino; Stefano Signoretti; Giuseppe Lazzarino; Antonio Belli Journal: Mol Med Date: 2014-03-24 Impact factor: 6.354
Authors: Brian J Soher; William E Wu; Assaf Tal; Pippa Storey; Ke Zhang; James S Babb; Ivan I Kirov; Yvonne W Lui; Oded Gonen Journal: NMR Biomed Date: 2014-09-05 Impact factor: 4.044
Authors: Katrin Beckmann; Inés Carrera; Frank Steffen; Lorenzo Golini; Patrick R Kircher; Uwe Schneider; Carla Rohrer Bley Journal: Acta Vet Scand Date: 2015-01-31 Impact factor: 1.695